in drug discovery
Management Board
Dr. Thomas Haehner, CEO
Dr. Thomas Haehner studied medicine at the Universities of Greifswald, Berlin and Ulm. During his doctoral thesis at the Institute of Physiological Chemistry (Ulm University, Germany) he worked on chemical inhibition-mechanisms of drug metabolism enzymes. After postdoctoral fellowships at the Institutes of Clinical Pharmacology and Toxicology (Basel University, Switzerland) and Physiological Chemistry (Ulm University) he joined the Federal State Program “Junge Innovatoren”, rewarding excellence in entrepreneurship and science. Dr. Thomas Haehner filed various patent applications and is co-founder of ACROVIS biostructures.
Contact
B.A. jur. Vladimir Nechaev, Business Development & Investor Relations
Head of Investor Relations and head of Business Development Russia of ACROVIS®biostructures Bakkalaureus juris (Bachelor of law) Vladimir Nechaev studied Economic and Law at the Institute for Foreign Economics at St. Petersburg from 1995 to 1999. Until 2000 he worked as chief executive (factory manager) at a Russian mid-tier company and ran an own business in Russia. From 2004 to 2008 he was chief executive of an affiliate of the international trust Bayer AG at the Koelnmesse instructing 350 employee. He acts as management consultant with the focus Russia and as German entrepreneur since 2006 (Nechaev Business Services). Mr. Nechaev is founder of the biggest German-speaking Portal about the Russian economy NBS-Research.com and developer of an own universal methodology for market investigation and cultivation as well as strategic collaboration with clients and political entities. He is accepted as the expert for economy in Russia by the German press and at universities such as the Cologne University of Applied Science and the University of Heidelberg. Hobby: second law studies at the University at Cologne.
Contact
Dr. Torsten Diesinger, CSO
Dr. Torsten Diesinger is Chief Scientific Officer at ACROVIS biostructures.
He studied medicine and philosophy at the University of Ulm (Germany) and Biochemistry and Molecular Cell Biology at the Private University of Witten/Herdecke (Germany).
Already since his doctoral thesis at the Institute of Physiological Chemistry at Ulm University Dr. Torsten Diesinger focused on molecular inhibition mechanisms of drug metabolizing enzymes by small molecules.
Dr. Torsten Diesinger is co-founder of ACROVIS biostructures and holder of a number of patents.
Contact